It is reported that the National Institutes of Health recently approved the first human clinical trial using the CRISPR gene editing technology known as "genetic scissors" to treat cancer, making this currently highly regarded biomedical technology only clinical trials in the United States. The US Food and Drug Administration approved a step away.
Industry insiders pointed out that gene editing technology has been hailed as the biggest breakthrough in the field of biotechnology in the century. Although this technology has been in existence for a long time, it has stagnated in animal experiments because of ethical and moral issues. The first US approval of the use of gene editing technology in human trials will be a epoch-making breakthrough in the medical community. In China, precision medicine has been selected into the “Thirteenth Five-Year Plan†project this year. The support of policy has brought strong catalysis to the development of China's gene editing technology. In the future, precision medical field will continue to have event or policy incentives. Relevant concept stocks suggest a bargain-hunting layout.
Affected by this, yesterday's precision medical concept sector changed, Ma Yinglong's intraday strong daily limit, Wuyuan Pharmaceutical, Lidman, Meikang Bio, Guangshengtang, Xiqiao Science and other stocks also rose more than 5%, respectively reached 6.31 %, 6.27%, 5.95%, 5.44% and 5.16%, in addition, the new open source, Zhongyuan Concord, Yuheng Pharmaceutical, Kehua Biological, Yiling Pharmaceutical and other stocks also rose significantly, the increase was above 2%.
In terms of capital flow, according to the statistics of the Market Research Center of Securities Daily, a total of 24 concept stocks in the sector yesterday showed a net inflow of large single funds, with an accumulated investment of 337 million yuan. Among them, Ma Yinglong (12,869.91 million yuan), Lidman (332.221 million yuan), Hengkang Medical (287.654 million yuan), Yiling Pharmaceutical (20.503 million yuan), Shuanglu Pharmaceutical (137.027 million yuan), Dean diagnosis ( The net inflow of large-capital funds such as 132.48 million yuan and Beilu Pharmaceutical (126.210 million yuan) was 10 million yuan.
Recently, the precise medical policy has been very popular. The National Health and Family Planning Commission Medical and Health Science and Technology Development Research Center issued a notice on publicizing the 2016 project plan for the National Key Research and Development Program “Precision Medical Researchâ€, and announced the “Special Medical Research†key project in 2016. Project information; The General Office of the State Council recently issued the "Guiding Opinions on Promoting and Regulating the Development of Big Data Applications for Health Care Medical ", deploying a new model of service through "Internet + Health Care" and fostering new developments.
Guohai Securities said that cell therapy and gene editing have achieved technological breakthroughs and policy relaxation, and it is expected to catalyze the precision medical sector in the short term. Immune cell therapy has achieved good clinical trial data in hematological tumors. Previously, the effect was not ideal in solid tumor tests, and solid tumors accounted for the majority of tumor types. It is recommended to focus on Anke Bio and Zuoli Pharmaceutical.
Great Wall Securities said that a breakthrough in the third-generation sequencing software technology has recently “fixed†the shortcomings of the three-generation sequencing technology with high error rate, highlighting the advantages of longer read lengths and lower sequencing costs, and is expected to advance the third-generation gene sequencing. The clinical application of technology, medium and long-term technological breakthroughs will reduce the cost of gene sequencing as a whole, the price of sequencing services can be more affordable for the population, with the release of downstream demand, the midstream service market is expected to continue to expand, continue to be optimistic about gene sequencing technology in the pharmaceutical industry In the investment opportunities, it is recommended to set the standard of Daan Gene on the dips. The market is expected to continue to maintain a volatile pattern in the near future. It is recommended to continue to pay attention to new medical reforms (prescription drug outflows, doctor resource outflows and testing services cooperation), review policies (new drug development and consistency evaluation) and performance improvement (increased blood product prices and children's drug demand). ) Investment opportunities.
ICU Bridge Type Ceiling-Mounted system,specially designed for intensive care rooms,the entire process wards, the recovery room.Supply flexible, first-rank nursing satisfy patient's separate treatment and nursing demand.Unique design lies in it all hides the electrical cable and pipeline in the ceiling-mounted arm.The modular design and multiple configurations.As clients' requirements,providing reasonable ICU Combination Ceiling-Mounted pendant (Apart Dry-Wet). Advanced spray technology, the intelligent combination of innovative ways to make the bridge pendant with diverse functions.
Icu Room Bridge,Medical Pendant System,Manual Crane,Motorized Pendant
Shandong Lewin Medical Equipment Co., Ltd. , https://www.lewinmed.com